HLS Therapeutics

HLS Therapeutics is a pharmaceutical company dedicated to providing access to critical treatments for patients and their caregivers, with a focus on trusted brand names. The company specializes in products targeting the central nervous system (CNS) and cardiovascular therapeutic areas. HLS Therapeutics operates in North American markets, with locations in Toronto, Montreal, and Philadelphia. The company sources its products from the drug’s originator or best-in-class manufacturing partners, ensuring high standards of quality in compliance with FDA and Health Canada regulations. HLS Therapeutics offers a robust product pipeline that includes treatments for cardiovascular and CNS conditions. The company supports Medications Return Programs managed by the Health Products Stewardship Association to ensure safe medication disposal. HLS Therapeutics has completed the acquisition of U.S. and Canadian rights to CLOZARIL and has licensed the rights for Vascepa and Trinomia in Canada. The company actively seeks acquisition opportunities in the pharmaceutical market to expand its commercial portfolio, focusing on CNS, cardiovascular, and selected disease states.